. 2016 Nov 11;101(4):913–925. doi: 10.1189/jlb.5MA0716-294R

TABLE 2.

IgG responses among Ngerenya 1998 cohort members, according to age group and parasitemic status

Antigens^b	n^c	All^a	Age group, yr^a			Sign.	P^d	Parasitemic status^a		Sign.	P^d
Antigens^b	n^c	All^a	2–5	6–14	18–81	Sign.	P^d	Apara.	Para.	Sign.	P^d
MSP1-19	143	0.07	0.02	0.04	0.45	^*	<0.001	0.08	0.06		0.667
		[0.01–0.49]	[0.00–0.11]	[0.01–0.21]	[0.11–0.88]			[0.00–0.51]	[0.02–0.47]
		35 (24.5)	3 (7.7)	10 (18.2)	22 (44.9)	^*	<0.001	22 (25.0)	13 (23.6)		0.854
MSP1-42	150	0.22	0.05	0.22	0.63	^*	<0.001^†	0.17	0.24		0.140^†
		[0.04–0.66]	[0.01–0.17]	[0.05–0.51]	[0.30–1.10]			[0.02–0.57]	[0.09–0.66]
		37 (24.7)	2 (4.7)	11 (19.3)	24 (48.0)	^*	<0.001	22 (24.2)	15 (25.4)		0.862
MSP2	143	0.41	0.04	0.51	0.74	^*	<0.001^†	0.15	0.60	^*	<0.001^†
		[0.06–0.91]	[0.00–0.44]	[0.13–0.90]	[0.22–1.32]			[0.02–0.82]	[0.22–1.21]
		35 (24.5)	3 (7.7)	13 (23.6)	19 (38.8)	^*	0.003	19 (21.6)	16 (29.1)		0.310
MSP2(FC27)	143	0.49	0.05	0.78	0.97	^*	<0.001^†	0.27	0.88	^*	<0.001^†
		[0.07–1.20]	[0.02–0.26]	[0.20–1.20]	[0.33–1.35]			[0.03–1.10]	[0.31–1.24]
		35 (24.5)	4 (10.3)	13 (23.6)	18 (36.7)	^*	0.016	18 (20.5)	17 (30.9)		0.157
MSP4	150	0.62	0.14	0.76	0.88	^*	<0.001^†	0.44	1.01	^*	<0.001^†
		[0.16–1.36]	[0.03–1.03]	[0.36–1.48]	[0.29–1.39]			[0.07–1.18]	[0.45–1.58]
		37 (24.7)	8 (18.6)	16 (28.1)	13 (26.0)		0.534	16 (17.6)	21 (35.6)	^*	0.012
AMA1	150	0.49	0.08	0.76	0.53	^*	<0.001^†	0.26	0.82	^*	<0.001^†
		[0.10–0.94]	[0.04–0.55]	[0.16–1.21]	[0.14–0.85]			[0.05–0.73]	[0.30–1.27]
		37 (24.7)	7 (16.3)	21 (36.8)	9 (18.0)	^*	0.025	11 (12.1)	26 (44.1)	^*	<0.001
AMA1(W2mef)	150	0.47	0.08	0.76	0.63	^*	<0.001^†	0.37	1.02	^*	<0.001^†
		[0.08–1.08]	[0.01–0.82]	[0.18–1.31]	[0.17–1.08]			[0.03–0.87]	[0.18–1.46]
		37 (24.7)	6 (14.0)	19 (33.3)	12 (24.0)		0.083	12 (13.2)	25 (42.4)	^*	<0.001
EBA140 RIII-V	143	0.14	0.03	0.17	0.46	^*	<0.001^†	0.10	0.19	^*	0.002^†
		[0.04–0.59]	[0.01–0.11]	[0.07–0.56]	[0.12–0.97]			[0.02–0.51]	[0.10–0.81]
		35 (24.5)	2 (5.1)	13 (23.6)	20 (40.8)	^*	0.001	18 (20.5)	17 (30.9)		0.157
EBA181 RIII-V	143	0.10	0.06	0.10	0.27	^*	<0.001^†	0.10	0.12		0.488^†
		[0.05–0.34]	[0.03–0.10]	[0.06–0.31]	[0.10–0.63]			[0.04–0.39]	[0.06–0.31]
		35 (24.5)	2 (5.1)	13 (23.6)	20 (40.8)	^*	0.001	25 (28.4)	10 (18.2)		0.166
EBA175 RIII-V	143	0.10	0.04	0.11	0.46	^*	<0.001^†	0.08	0.15		0.065^†
		[0.04–0.60]	[0.02–0.08]	[0.04–0.47]	[0.09–1.96]			[0.03–0.58]	[0.06–0.68]
		35 (24.5)	3 (7.7)	11 (20.0)	21 (42.9)	^*	<0.001	21 (23.9)	14 (25.5)		0.830
EBA175-F2	150	0.18	0.05	0.24	0.34	^*	<0.001^†	0.16	0.25	^*	0.031^†
		[0.06–0.51]	[0.01–0.09]	[0.13–0.47]	[0.11–0.95]			[0.04–0.43]	[0.08–0.84]
		37 (24.7)	3 (7.0)	13 (22.8)	21 (42.0)	^*	<0.001	18 (19.8)	19 (32.2)		0.085
EBA175	150	0.04	0.01	0.06	0.18	^*	<0.001^†	0.03	0.05		0.053^†
(W2mef)		[0.01–0.25]	[0.00–0.02]	[0.02–0.22]	[0.04–0.79]			[0.01–0.20]	[0.02–0.29]
		37 (24.7)	3 (7.0)	13 (22.8)	21 (42.0)	^*	<0.001	21 (23.1)	16 (27.1)		0.575
RH2-2530	150	0.22	0.14	0.29	0.34	^*	0.002^†	0.20	0.31		0.082^†
		[0.13–0.63]	[0.08–0.44]	[0.17–0.78]	[0.17–0.77]			[0.12–0.55]	[0.16–0.86]
		37 (24.7)	4 (9.3)	18 (31.6)	15 (30.0)	^*	0.021	16 (17.6)	21 (35.6)	^*	0.012
RH2-2030	150	0.23	0.14	0.26	0.30	^*	0.013^†	0.21	0.27		0.073^†
		[0.13–0.46]	[0.08–0.36]	[0.16–0.50]	[0.17–0.56]			[0.11–0.41]	[0.16–0.58]
		37 (24.7)	6 (14.0)	16 (28.1)	15 (30.0)		0.151	18 (19.8)	19 (32.2)		0.085
RH4-A3	150	0.12	0.08	0.11	0.22	^*	0.005	0.10	0.15		0.164^†
		[0.04–0.36]	[0.02–0.21]	[0.05–0.28]	[0.07–0.61]			[0.02–0.37]	[0.08–0.36]
		37 (24.7)	4 (9.3)	12 (21.1)	21 (42.0)	^*	0.001	23 (25.3)	14 (23.7)		0.830
SERA5	150	0.14	0.07	0.17	0.30	^*	<0.001^†	0.09	0.23	^*	0.009^†
		[0.05–0.38]	[0.04–0.17]	[0.05–0.36]	[0.09–0.64]			[0.05–0.34]	[0.10–0.47]
		37 (24.7)	2 (4.7)	13 (22.8)	22 (44.0)	^*	<0.001	21 (23.1)	16 (27.1)		0.575
Pf41	130	0.21	0.11	0.28	0.22		0.087^†	0.16	0.28		0.052
		[0.05–0.42]	[0.04–0.28]	[0.08–0.45]	[0.04–0.42]			[0.04–0.37]	[0.08–0.44]
		32 (24.6)	4 (12.1)	16 (31.4)	12 (26.1)		0.130	16 (20.0)	16 (32.0)		0.122
Pf38	130	0	0.00	0.01	0.01		0.277	0.00	0.03		0.131^†
		[0–0.12]	[0–0.04]	[0–0.13]	[0–0.20]			[0–0.10]	[0–0.15]
		32 (24.6)	6 (18.2)	13 (25.5)	13 (28.3)		0.581	18 (22.5)	14 (28.0)		0.479
Pf12	130	0.32	0.22	0.44	0.36		0.143^†	0.21	0.47	^*	<0.001^†
		[0.07–0.70]	[0–0.61]	[0.15–0.89]	[0.12–0.57]			[0.04–0.57]	[0.24–1.05]
		32 (24.6)	7 (21.2)	17 (33.3)	8 (17.39)		0.166	12 (15.0)	20 (40.0)	^*	<0.001
Schizont	150	0.25	0.11	0.26	0.66	^*	<0.001^†	0.20	0.34		0.082^†
extract		[0.12–0.57]	[0.04–0.23]	[0.15–0.47]	[0.27–1.00]			[0.08–0.64]	[0.19–0.53]
		37 (24.7)	1 (2.3)	8 (14.0)	28 (56.0)		<0.001	25 (27.5)	12 (20.3)		0.322

Apara., Aparasitemic; Para., parasitemic; RH, reticulocyte-binding homologue, Sign., significance.

For each antigen represented, figures reflect: median value (row 1); 25–75th percentile ([p25–p75]; row 2); and high responders n (%; row 3). High responders by ELISA are those with absorbance ≥75th percentile.

All alleles are 3D7 unless otherwise specified.

Number of samples tested by ELISA for each antigen.

P values calculated using a Kruskal-Wallis test or χ² test.

P ≤ 0.05 is significant.

^†

P ≤ 0.05 is significant, comparing antibody levels among children only (n = 100), children 2–5 and children 6–14 yr, using a Wilcoxon rank sum test (P values not shown).